DOCS — Doximity, Inc.

Doximity Q3 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $185.1 million, up 10% year-over-year, exceeding guidance by 2%.
• Adjusted EBITDA: $111.4 million, with a margin of 60%, surpassing guidance by 7%.
• Net Revenue Retention Rate: 112% on a trailing twelve-month basis; 117% for the top 20 customers.
• Free Cash Flow: $58.5 million generated in Q3.
• Share Repurchase: $196.8 million in shares repurchased during the quarter; $83 million remaining in the existing program, with an additional $500 million open-ended repurchase authorization approved.

2. Strategic Updates and Business Highlights

• User Growth: Surpassed 3 million registered members, including over 85% of U.S. physicians and two-thirds of nurse practitioners and physician assistants.
• AI Product Adoption: Over 300,000 unique prescribers used Doximity's AI tools in Q3, with significant engagement noted.
• Telehealth Leadership: Doximity Dialer ranked as the top telehealth platform for the fifth consecutive year.
• AI Integration: The company is focusing on building trusted AI tools with a peer review system involving over 10,000 physician experts.
• Market Positioning: Doximity has established itself as a trusted platform for physicians, with strong engagement across its digital offerings.

3. Forward Guidance and Outlook

• Q4 2026 Guidance: Revenue expected between $143 million and $144 million, reflecting 4% growth at the midpoint. Adjusted EBITDA projected between $63.5 million and $64.5 million.
• Full Fiscal Year 2026 Guidance: Revenue expected between $642.5 million and $643.5 million, representing 13% growth at the midpoint. Adjusted EBITDA anticipated between $355.5 million and $356.5 million.
• Market Growth Expectation: The company expects to exit calendar year 2026 with double-digit growth, driven by unspent client budgets and the introduction of commercial AI products.

4. Bad News, Challenges, or Points of Concern

• Policy Headwinds: Uncertainty surrounding recent policy changes, particularly the "most favored nation" agreements impacting pharma budgets, led to delays in client spending and signing contracts.
• Lower Q4 Expectations: The company noted that the midpoint of its annual outlook remains unchanged due to lower revenue expectations for Q4 and increased AI infrastructure investments.
• Gross Margin Decline: Non-GAAP gross margin decreased to 91% from 93% year-over-year, attributed to higher AI infrastructure costs.

5. Notable Q&A Insights

• Market Growth Dynamics: Management indicated that the market is expected to grow around 5% in 2026, with Doximity aiming to outpace this growth through innovation and strong ROI offerings.
• AI Monetization Strategy: While the company has not included AI revenue in current guidance, it plans to introduce commercial AI products later in the year, which could tap into innovation budgets.
• Client Budgeting Trends: There is a notable shift in how pharma clients are approaching their budgets, with some funds being delayed, but intent to spend remains strong.
• Competitive Landscape: Doximity's strong user base and trust among physicians position it well against competitors, particularly in the AI space, where it aims to differentiate through its peer review system.

Overall, Doximity reported solid financial performance in Q3 2026, with strong user engagement and strategic initiatives in AI, despite facing challenges related to policy uncertainties and market dynamics. The company remains optimistic about future growth driven by innovation and increased client spending.